Focused On-demand Library for Cartilage oligomeric matrix protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P49747

UPID:

COMP_HUMAN

Alternative names:

Thrombospondin-5

Alternative UPACC:

P49747; B4DKJ3; O14592; Q16388; Q16389; Q2NL86; Q8N4T2

Background:

Cartilage oligomeric matrix protein, also known as Thrombospondin-5, plays a crucial role in maintaining the structural integrity of cartilage. It interacts with extracellular matrix proteins like collagens and fibronectin, facilitating chondrocyte interaction with the cartilage extracellular matrix. Its involvement in osteoarthritis pathogenesis and apoptosis suppression highlights its significance in cellular processes.

Therapeutic significance:

Linked to diseases such as Multiple epiphyseal dysplasia 1, Pseudoachondroplasia, and Carpal tunnel syndrome 2, understanding the role of Cartilage oligomeric matrix protein could open doors to potential therapeutic strategies. Its disease associations underscore its potential as a target for therapeutic intervention in skeletal dysplasias and related conditions.